
EC Approves Merck’s CAPVAXIVE® Vaccine for Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia
Merck announced that the European Commission (EC) has approved CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) for active immunization for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae serotypes 3, 6A, 7F, 8, 9N, …